The lawsuit claims that the two companies, Novo Nordisk and Eli Lilly, knew of the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues, including gastroparesis and gastroenteritis. Their failure to disclose information that they possessed regarding the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues, including gastroparesis and gastroenteritis, rendered the warnings for this medication inadequate, it continues
Inflammation and oxidative stress levels in heart tissue were evaluated
[PubMed 6028876] 15
If you have difficulty swallowing pills, the orally disintegrating tablets or delayed-release oral suspension may be better options
It requires daily dosing compared to Wegovys weekly injection, which is a practical consideration for many patients
Sikiric P, Boban Blagaic A, Strbe S, Beketic Oreskovic L, Oreskovic I, Sikiric S, et al
